BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced the approval of its medical device license from the National Medical Products Administration (NMPA) for a novel gene methylation detection kit. The kit employs fluorescence PCR technology to assess the combined methylation status of the SDC2, ADHFE1, and PPP2R5C genes.
Designed for in vitro qualitative detection, the kit analyzes methylation in intestinal exfoliated cells derived from human fecal samples, aiming to evaluate the risk of colorectal cancer (CRC). Its performance exceeds that of traditional fecal occult blood tests, positioning it as a promising tool for early CRC screening, with the potential to lower both incidence rates and mortality associated with the disease.- Flcube.com
